Immune checkpoint inhibitors combined with targeted therapy for long-term survival in advanced pulmonary squamous cell carcinoma after first-line failure: A case report and literature review.

Medicine (Baltimore) · 2025 · PMC12187345 · PMID 40550073

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

For patients receiving the combination therapy, the median PFS was slightly longer than that of those receiving anlotinib alone (4.2 months vs 3.1 months), although the difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.